NervGen Pharma Corp. announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will continue to formally support the company as a consultant. Mr. Brennan has also been appointed as a member of NervGen's Board of Directors.

The company also announced the appointment of Mr. Lloyd Mackenzie in the newly created position of Chief Operating Officer, also effective immediately. Mr. Brennan has held a number of executive positions within biotech, including at Eupraxia Pharmaceuticals Inc., Aquinox Pharmaceuticals Inc., Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation), Altair Therapeutics Inc., Aspreva Pharmaceuticals Corp. and AnorMED Inc.